Anti-anaphylactic activities of a new benzopyranopyridine derivative Y-12,141 in rats and guinea pigs.
The active anaphylactic bronchoconstriction of rats mediated by IgE-like antibody against DNP-Ascaris was inhibited by intravenous and intratracheal treatment with Y-12,141 in a dose-dependent manner. In both routes, the inhibitory effect of Y-12,141 on this response was more potent than that of disodium cromoglycate (DSCG). The oral administration of Y-12,141 also produced a similar inhibition of the response. The passive anaphylactic bronchoconstriction of guinea pigs mediated by IgG-like antibody against egg albumin was also prevented dose-dependently by treatment with Y-12,141 given intravenously, but not with DSCG. The present results suggest that Y-12,141 may be effective for the treatment of allergic bronchial asthma.
D000707:Anaphylaxis / Q000188:drug therapy*; D000818:Animals; D001249:Asthma / Q000188:drug therapy*; D001393:Azoles / Q000627:therapeutic use*; D002867:Chromones / Q000008:administration & dosage / Q000627:therapeutic use*; D004205:Cromolyn Sodium / Q000008:administration & dosage / Q000627:therapeutic use; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D006168:Guinea Pigs; D006636:Histamine Release; D008168:Lung / Q000276:immunology; D008297:Male; D011817:Rabbits; D051381:Rats; D013189:SRS-A / Q000378:metabolism; D013777:Tetrazoles / Q000008:administration & dosage / Q000627:therapeutic use*
D001393:Azoles; D002867:Chromones; D013189:SRS-A; D013777:Tetrazoles; C020178:traxanox; D004205:Cromolyn Sodium